Drug Profile
Research programme: influenza-A virus H5N1 vaccine - Replikins
Alternative Names: H5N1 Synthetic Replikins VaccineLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Replikins
- Class Influenza A virus H5N1 vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (Intranasal, Aerosol)
- 31 Dec 2009 Preclinical trials in Influenza A virus H5N1 subtype infections (prevention) in USA (Intranasal)
- 31 Dec 2009 Preclinical pharmacodynamics data from in avian Influenza-A virus H5N1 infections published Replikins